Potential pitfalls in incorporating plasma Epstein‐Barr virus DNA in the management of nasopharyngeal carcinoma

Background This study identifies potential pitfalls in incorporating plasma Epstein‐Barr virus (EBV) DNA into the management of nasopharyngeal carcinoma (NPC). Methods A total of 208 NPC patients without distant metastasis who received radical treatment and had measurements of EBV DNA at baseline, 8...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2020-03, Vol.42 (3), p.446-455
Main Authors: Wong, Edwin C. Y., Hung, Jessica L. C., Ng, Wai T.
Format: Article
Language:English
Subjects:
biomarker
Deoxyribonucleic acid
DNA
Endoscopy
Epstein-Barr virus
Head and neck
Metastases
Nasopharyngeal carcinoma
pitfalls
plasma EBV DNA
prognostication
Radiation therapy
Survival
Throat cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background This study identifies potential pitfalls in incorporating plasma Epstein‐Barr virus (EBV) DNA into the management of nasopharyngeal carcinoma (NPC). Methods A total of 208 NPC patients without distant metastasis who received radical treatment and had measurements of EBV DNA at baseline, 8 weeks and 26 weeks postradiotherapy were analyzed. Prognostic and predictive values at each time‐point were compared. Results Risk stratification by pretreatment level failed to identify a poor prognostic group. Detectable EBV DNA at 8 weeks and 26 weeks postradiotherapy were both associated with significantly poorer 5‐year disease‐free survival (HR 0.30, P 
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.26018